Physician profile
Eric G George
NPI 1346289493
$2,530.70
in general payments reported to CMS, 2019-2025
32 companies · $693 in 2025
The $693 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $81.76 · 2021: $277 · 2022: $374 · 2023: $416 · 2024: $526 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $315.60 | 2019-2025 | Tryptyr |
| Oyster Point Pharma, INC. | $299.07 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $232.68 | 2019-2025 | Cequa |
| Allergan, INC. | $215.83 | 2019-2022 | |
| Abbvie INC. | $190.43 | 2022-2024 | |
| Tarsus Pharmaceuticals, INC. | $152.82 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $140.93 | 2024 | Oxervate |
| Amgen INC. | $137.89 | 2025 | Tepezza |
| Harrow Eye, LLC | $119.02 | 2024-2025 | Vevye, Triesence |
| Merz Pharmaceuticals, LLC | $73.32 | 2023-2025 | Xeomin |
| Mallinckrodt Hospital Products INC. | $70.07 | 2022-2023 | Acthar |
| Horizon Therapeutics Plc | $65.81 | 2019-2023 | Tepezza |
| Ocular Therapeutix, INC. | $56.14 | 2022-2024 | Dextenza |
| Ani Pharmaceuticals, INC. | $54.40 | 2024-2025 | Purified Cortrophin Gel |
| Braintree Laboratories, INC. | $44.83 | 2022-2023 | Sutab |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $34.92 | 2022-2023 | Biotrue One Day |
| Thea Pharma INC. | $30.21 | 2022-2024 | Iyuzeh |
| Sight Sciences, INC. | $26.65 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $26.62 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $24.44 | 2020 | |
| Alexion Pharmaceuticals, INC. | $23.49 | 2022 | |
| Apellis Pharmaceuticals, INC. | $22.45 | 2025 | Syfovre |
| Biotissue Holdings INC. | $22.25 | 2023 | |
| Shire North American Group INC | $21.31 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.32 | 2023 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Aerie Pharmaceuticals, INC. | $17.08 | 2021 | |
| Eyepoint US, INC. | $14.84 | 2019 | |
| Glaukos Corporation | $14.50 | 2025 | Idosetr |
| Astellas Pharma US INC | $14.33 | 2025 | Izervay |
| Tearlab Corp | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.